Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Free Subscription


2 Cephalalgia
12 Headache

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles


  1. ALBERS L, Kries RV, Straube A, Heinen F, et al
    Age- and sex-specific first health care use for migraine in 2016 in children and adolescents from prospectively collected health insurance data in Germany.
    Cephalalgia. 2019 Apr 11:333102419844543. doi: 10.1177/0333102419844543.
    PubMed     Text format     Abstract available

  2. WEN KX, Ikram MA, Franco OH, Vernooij M, et al
    Association of migraine with calcification in major vessel beds: The Rotterdam Study.
    Cephalalgia. 2019 Apr 8:333102419843148. doi: 10.1177/0333102419843148.
    PubMed     Text format     Abstract available


  3. RUSSO A, Silvestro M, Tessitore A, Tedeschi G, et al
    Recent Insights in Migraine With Aura: A Narrative Review of Advanced Neuroimaging.
    Headache. 2019;59:637-649.
    PubMed     Text format     Abstract available

  4. VIGANO A, Manica A, Di Piero V, Leonardi M, et al
    Did Going North Give Us Migraine? An Evolutionary Approach on Understanding Latitudinal Differences in Migraine Epidemiology.
    Headache. 2019;59:632-634.
    PubMed     Text format     Abstract available

  5. KLAN T, Liesering-Latta E, Gaul C, Martin PR, et al
    An Integrative Cognitive Behavioral Therapy Program for Adults With Migraine: A Feasibility Study.
    Headache. 2019 Apr 10. doi: 10.1111/head.13532.
    PubMed     Text format     Abstract available

    Toward a Philosophy of Migraine.
    Headache. 2019;59:481-483.
    PubMed     Text format    

  7. RIST PM, Hernandez A, Bernstein C, Kowalski M, et al
    The Impact of Spinal Manipulation on Migraine Pain and Disability: A Systematic Review and Meta-Analysis.
    Headache. 2019;59:532-542.
    PubMed     Text format     Abstract available

  8. STEINER TJ, Tfelt-Hansen P
    Misused and Misleading: "100% Response Rate" to Galcanezumab in Patients With Episodic Migraine.
    Headache. 2019;59:626.
    PubMed     Text format    

  9. CHARLES JA, Rapoport AM
    The American Headache Society's Position Statement on Integrating New Migraine Treatments into Clinical Practice - Comments.
    Headache. 2019;59:629.
    PubMed     Text format    

  10. ANSARI H
    Choose Wisely: Adapt the Classification Characteristic for Migraine Trigger Points.
    Headache. 2019;59:621-622.
    PubMed     Text format    

  11. ROSEN N, Pearlman E, Ruff D, Day K, et al
    Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine.
    Headache. 2019;59:627-628.
    PubMed     Text format    

  12. BOES CJ
    Comment on "Chronic Migraine - Evolution of the Concept and Clinical Implications".
    Headache. 2019;59:623.
    PubMed     Text format    

  13. SILBERSTEIN SD, McAllister P, Ning X, Faulhaber N, et al
    Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.
    Headache. 2019 Apr 12. doi: 10.1111/head.13534.
    PubMed     Text format     Abstract available

  14. HINDIYEH NA, Kellerman DJ, Schmidt PC
    Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials.
    Headache. 2019 Apr 6. doi: 10.1111/head.13511.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.